International Psoriasis Council
Advancing Knowledge. Improving Care.
Boehringer Ingelheim announced earlier this month that the U.S. Food and Drug Administration (FDA) has approved SPEVIGO® (spesolimab-sbzo) for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients aged 12 and above. SPEVIGO® has also expanded approval for use in China, marking approval in 48 countries.
Learn more about SPEVIGO® – Highlights of Prescribing Information
Experts from across five continents discuss regional biosimilar uptake and practical strategies for optimizing psoriasis treatment in this IPC-led symposium at ICD 2025 in Rome.
Oruka has joined the International Psoriasis Council as a 2025 Bronze Level Corporate Member, bringing its best-in-class monoclonal antibody therapies to advance psoriasis and psoriatic arthritis research and patient care.
Join IPC in welcoming Alumis Inc. as a 2024 Bronze Level Corporate Member! Discover how Alumis’ innovative research and dedication to patient care support IPC’s global mission to enhance and improve psoriasis treatment.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.
